MBA BS - Aethlon Medical Chief Officer
| AEMD Stock | USD 0.37 0.02 5.71% |
Executive
MBA BS is Chief Officer of Aethlon Medical
| Age | 53 |
| Address | 11555 Sorrento Valley Road, San Diego, CA, United States, 92121 |
| Phone | 619 941 0360 |
| Web | https://www.aethlonmedical.com |
Aethlon Medical Management Efficiency
The company has return on total asset (ROA) of (0.5046) % which means that it has lost $0.5046 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.0538) %, meaning that it created substantial loss on money invested by shareholders. Aethlon Medical's management efficiency ratios could be used to measure how well Aethlon Medical manages its routine affairs as well as how well it operates its assets and liabilities. As of December 18, 2024, Return On Tangible Assets is expected to decline to -1.55. The current year's Return On Capital Employed is expected to grow to -1.87. At present, Aethlon Medical's Non Current Assets Total are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 326.7 K, whereas Intangible Assets are forecasted to decline to 1,045.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Kristine Williams | Rapid Micro Biosystems | N/A | |
| Michael Wysocki | Rapid Micro Biosystems | N/A | |
| Sean Wirtjes | Rapid Micro Biosystems | 55 | |
| Amy Treadwell | Neuropace | N/A | |
| John Kowalczyk | Nuwellis | N/A | |
| Jonelle Burnham | CVRx Inc | 53 | |
| Michael Marcroft | SINTX Technologies | N/A | |
| Kelley Nicholas | Neuropace | N/A | |
| David OBrien | SINTX Technologies | 59 | |
| Eryn Graham | Bluejay Diagnostics | N/A | |
| Kimberly Bambach | Tivic Health Systems | 53 | |
| Leah Akin | Neuropace | N/A | |
| Ruth Hembree | Vivos Therapeutics | N/A | |
| Sean CPA | Rapid Micro Biosystems | 55 | |
| Ryan Bock | SINTX Technologies | N/A | |
| Robert John | CVRx Inc | N/A | |
| Deina Walsh | Bone Biologics Corp | 60 | |
| Les DeLuca | Bluejay Diagnostics | N/A | |
| Vitaliy Epshteyn | Nuwellis | 46 | |
| Johnny MD | Delcath Systems | 59 | |
| David Hoffman | Delcath Systems | N/A | |
Management Performance
| Return On Equity | -1.05 | ||||
| Return On Asset | -0.5 |
Aethlon Medical Leadership Team
Elected by the shareholders, the Aethlon Medical's board of directors comprises two types of representatives: Aethlon Medical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aethlon. The board's role is to monitor Aethlon Medical's management team and ensure that shareholders' interests are well served. Aethlon Medical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aethlon Medical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MBA BS, Chief Officer | ||
| MD Fisher, Director CEO | ||
| Steven MD, Chief Officer | ||
| Richard Tullis, Chief Science Officer and VP | ||
| Lee Arnold, Chief Officer | ||
| James MBA, CFO, CEO | ||
| Sunil Sawhney, Head Studies |
Aethlon Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aethlon Medical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.05 | ||||
| Return On Asset | -0.5 | ||||
| Current Valuation | (954.72 K) | ||||
| Shares Outstanding | 13.96 M | ||||
| Shares Owned By Insiders | 0.50 % | ||||
| Shares Owned By Institutions | 3.09 % | ||||
| Number Of Shares Shorted | 203.4 K | ||||
| Price To Earning | (1.14) X | ||||
| Price To Book | 0.85 X | ||||
| Price To Sales | 2.37 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Aethlon Medical is a strong investment it is important to analyze Aethlon Medical's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Aethlon Medical's future performance. For an informed investment choice regarding Aethlon Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aethlon Medical. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. For information on how to trade Aethlon Stock refer to our How to Trade Aethlon Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aethlon Medical. If investors know Aethlon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aethlon Medical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.79) | Revenue Per Share 0.236 | Quarterly Revenue Growth 42.782 | Return On Assets (0.50) | Return On Equity (1.05) |
The market value of Aethlon Medical is measured differently than its book value, which is the value of Aethlon that is recorded on the company's balance sheet. Investors also form their own opinion of Aethlon Medical's value that differs from its market value or its book value, called intrinsic value, which is Aethlon Medical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aethlon Medical's market value can be influenced by many factors that don't directly affect Aethlon Medical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aethlon Medical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Aethlon Medical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aethlon Medical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.